№ 4 / 2016 / 15-24

Targeted pharmacodynamic of subtilisins

Author: Madonov P.G.¹, Mishenina S.V.², Kinsht D.N.³, Kikhtenko N.V.⁴

Abstract

Subtilisin is one of the proteolytic enzymes. It is produced by bacteria of the genus Bacillus subtilis and has great potential in pharmacology of thrombosis. Direct thrombolytic effect and no side effects similar to those of widely used in the last 20 years plasminogen activators lead to this opportunity. Recent studies of the clinical use of subtilisin have shown their effectiveness not only for the treatment of thrombosis, but also for the prevention of cardiovascular disease and dementia. However, the use of subtilisin in medicine is limited by its low bioavailability. Trombovazim® is a new domestic product, wich is based on pegylated subtilisin and created using technology of radiation synthesis. Trombovazim® has targeted thrombolytic, cardioprotective and anti-inflammatory action. Today Trombovazim® is the only registered oral thrombolytic. Immobilized subtilisin are broad prospects for introduction in clinical practice.

Key words

Trombovazim, anticoagulant activity, myocardial infarction, nattokinase, subtilisins, venous sinus thrombosis, thrombolytic therapy

References

Alekseev A.A., Koutsenogiy P.K., Miroshnikov P.N. et al. Isolation and properties of fibrinolytic subtilisin-like serine protease secreted by the Bucillus subtilis strain B-2805. // Doklady Biochemistry and Biophysics. 2014. 455. (1). 72-75.
Auslender V.L., Bryazgin A.A., Voronin L.A. et al. Electron accelerator ILU series and their use in industry and medicine. // XI International Meeting on the Application of Charged Particle Accelerators in industry and medicine: a collection of the reports. SPb., 2005. 78-81.
Balaban N.P., Sharipova M.R. Practical application of bacillary protease. // Scientists notes of the Kazan University. Series: Science. 2011. 153. (2). 29-40.
Belousova N.Yu., Mazunin I.Yu., Koltchik O.V. et al. Experience of national preparation Trombovazim in combination therapy of retinal vein occlusion. // Man and medicine: a collection of materials XVII Russian Congress. M., 2010. 47.
Buevich E.I., Kotovshikova E.F., Syulzhina E.N. et al. Endothelium in acute myocardial infarction before and after Trombovazim® therapy. // Thrombosis, hemostasis and rheology. 2009. 3. 33-37.
Vyshlov E.V., Batalov R.E., Markov V.A. et al. Comparative efficacy of enzyme medication with thrombolytic effect in atrium thrombosis and spontaneous echo-contrast phenomenon in patients with atrial fibrillation. // Russian Cardiology Journal. 2015. 9. 71-74.
Vyshlov E.V., Markov V.A., Popov S.V. First experience of Trombovazime using for lysis of atrial thrombus in patients with atrial fibrillation. // Siberian Medical Journal. 2011. 1. 102-105.
Dygai A.M., Artamonov A.V., Bekarev A.A. et al. "Nanotechnology in Pharmacology", М., 2011. 136 с.
Kinsht D.N., Vereschagin E.I., Madonov P.G. et al. Efficacy Trombovazim drug in the treatment of chronic venous insufficiency. // Man and medicine: a collection of materials VII Russian Congress. M., 2009. 127-128.
Lutova L.V., Andreenko G.V., Karabasova M.A. et al. Research thrombolytic properties of thiol dependent serine proteinase (TSP) from Thermoactinomyces vulgaris in vivo. // J. Appl. biochemical and microbiology. 1990. 26. (5). 623-628.
Madonov P.G. Pharmacological properties and clinical effects of protein-polymer drugs, created by electron-beam synthesis: Abstract Dissertation. … Doctor of Medical Sciences. Tomsk, 2012.
Madonov P.G., Ershov K.I., Dubrovin A.V. et al. Electron-beam modification of preparations of the albuminous nature for improvement of their pharmacological properties. // Medicine and education in Siberia. 2013. 4. http://www.ngmu.ru/cozo/mos/article/pdf.php?id=1115.
Madonov P.G., Kinsht D.N., Ershov K.I. et al. Experience with clinical administration of new drug Thrombovasim® in vascular surgery. // Angiology and Vascular Surgery. 2015. 21. (1). 99-104.
Madonov P.G., Marinkin I.O., Kuleshov V.M. et al. The effectiveness of the preparation Trombovazim in chronic venous insufficiency under using hormone replacement therapy and hormonal oral contraceptives. // Man and medicine: a collection of materials XVII Russian Congress. M., 2010. 175.
Plotnikov M.B., Dygai A.M., Aliev O.I. et al. Antithrombotic and thrombolytic effects of a new proteolytic preparation Trombovazim (Russia). // Bulletin of Experimental Biology and Medicine. 2009. Т. 147. № 4. С. 438-440.
Solovyev M.A. Pleiotropic effects of oral fibrinolytic in the treatment of patients with coronary heart disease: angina FC I-II, 0-1 NC: Abstract Dissertation ... Candidate of medical sciences. Tomsk, 2011.
Soshenko D.G., Fokin A.A. Life quality evaluation in patients with inferior vena cava occlusion and experience use of new drug Trombovazim. // Thrombosis, hemostasis and rheology. 2011. 2. 59-64.
Troitskii A.V. The development of process for the drugs preparation based on protease immobilized Bac.subtilis: Abstract Dissertation ... Candidate of medical sciences. Novosibirsk, 1998
Trofimov A.O., Kravets L.Y. On the question of fibrinolysis in intracranial hemorrhage. // V Congress of Neurosurgeons of Russia: Congress materials. Ed. Safina Sh.M. Ufa^ Bashkortostan Health. 2009. 464.
Baharifar H., Tavoosidana G., Karimi R. et al. Optimization of Self-Assembled Chitosan/Streptokinase Nanoparticles and Evaluation of Their Cytotoxicity and Thrombolytic Activity. // J Nanosci Nanotechnol. 2015. 15. (12). 10127-10133.
Bi Q., Han B., Feng Y. et al. Antithrombotic effects of a newly purified fibrinolytic protease from Urechis unicinctus. // Thrombosis Research. 2013. 132. (2). e135-e144.
Cesarone M.R., Belcaro G., Nicolaides A.N. et al. Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial // Angiology. 2003. 54. (5). 531-539.
Choi D.B., Cha W.-S., Park N. et al. Purification and characterization of a novel fibrinolytic enzyme from fruiting bodies of Korean Cordyceps militaris // Bioresource Technology. 2011. 102. (3). 3279-3285.
Efficacy and Safety of Natto Extract. Clinical trial NCT00447434. https://clinicaltrials.gov/ct2/show/NCT00447434?term=NCT00447434&rank=1.
Fujita M., Hong K., Ito Y. et al. Thrombolytic Effect of Nattokinase on a Chemically Induced Thrombosis Model in Rat // Biological & Pharmaceutical Bulletin. 1995. 18. (10). 1387-1391.
Fujita M., Hong K., Ito Y. et al. Transport of Nattokinase across the Rat Intestinal Tract // Biological & Pharmaceutical Bulletin. 1995. 18. (9). 1194-1196.
Hsia C.H., Shen M.C., Lin J.S. et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects // Nutrient Research. 2009. 29. (3). 145-220.
Hsu R.L., Lee K.T., Wang J.H. et al. Amyloid-Degrading Ability of Nattokinase from Bacillus subtilis Natto // J. Agric. Food Chem. 2009. 57. (2). 503–508.
Kim J.Y., Gum S.N., Paik J.K. et al. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. // Hypertension Research. 2008. 31. (8). 1583–1588.
Kim J.Y., Gum S.N., Paik J.K.. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial // Hypertension Research. 2008. 31. 1583–1588.
Kotb E. Activity assessment of microbial fibrinolytic enzymes. // Appl Microbiol Biotechnol. 2013. 97. (15). 6647-6665.4
Lampe B.J., English J.C. Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. // Food Chem Toxicol. 2016. 88. 87-99.
Lee A.J. Mowbray P.I. Lowe G.D. et al. Blood Viscosity and Elevated Carotid Intima-Media Thickness in Men and Women: The Edinburgh Artery Study //. Circulation. 1998. 97. 1467-1473.
Mahajan P.M., Nayak S., Lele S.S. Fibrinolytic enzyme from newly isolated marine bacterium Bacillus subtilis ICTF-1: Media optimization, purification and characterization. // Journal of Bioscience and Bioengineering. 2012. 113. (3). 307-314.
Majumdar S., Sarmah B., Gogoi D. et al. Characterization, mechanism of anticoagulant action, and assessment of therapeutic potential of a fibrinolytic serine protease (Brevithrombolase) purified from Brevibacillus brevis strain FF02B // Biochimie. 2014. 103. 50-60.
Maruyama M., Sumi H. (eds): Effect of natto diet on blood pressure, in Basic and Clinical Aspects of Japanese Traditional Food Natto II. Japan Technology Transfer Association (JTTAS). 1998. 1-3.
Mine Y., Wong A.H.K., Jiang B. Fibrinolytic enzymes in Asian traditional fermented foods. // Food Research International. 2005. 38. (3). 243-250.
Mukherjee A.K., Rai S.K., Thakur R. et al. Bafibrinase: A non-toxic, non-hemorrhagic, direct-acting fibrinolytic serine protease from Bacillus sp. strain AS-S20-I exhibits in vivo anticoagulant activity and thrombolytic potency. // Biochimie. 2012. 94. (6). 1300-1308.
Nattokinase Atherothrombotic Prevention Study (NAPS). Clinical trial NCT02080520. https://clinicaltrials.gov/ct2/show/NCT02080520?term=NCT02080520&rank=1.
Ogasawara K., Inoue K., Park S. et al. Effects of Nattokinase on Blood Pressure: A Randomized, Controlled Trial. // Hypertension Research. 2008. 31. 8. 1583–1588.
Peng Y., Yang X., Zhang Y. Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo. // Applied Microbiology and Biotechnology. 2005. 69. (2). 126-132.
Simkhada J.R., Cho S.S., Mander P. et al. Purification, biochemical properties and antithrombotic effect of a novel Streptomyces enzyme on carrageenan-induced mice tail thrombosis model. // Thrombosis Research. 2012. 129. (2). 176-182.
Spreer A., Rüchel R., Reichard U. Characterization of an extracellular subtilisin protease of Rhizopus microsporus and evidence for its expression during invasive rhinoorbital mycosis. // Med Mycol. 2006. 44. (8). 723-731.
Suzuki Y., Kondo K., Ichise H. et al. Dietary supplementation with fermented soybeans suppresses intimal thickening // Nutrition. 2003. 19. (3). 261-264.
Suzuki Y., Kondo K., Matsumoto Y. et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery // Life Sciences. 2003. 73. (10). 1289-1298.
Tai M.W., Sweet B.V. Nattokinase for prevention of thrombosis // Am J Health Syst Pharm. 2006. 63. (12). 1121-1123.
Vaidya B., Nayak M.K., Dash D. et al. Development and characterization of highly selective target-sensitive liposomes for the delivery of streptokinase: in vitro/in vivo studies // Drug Deliv. 2016. 23. (3). 801-807.
Wang C., Ji B., Cao Y. et al. (Evaluating thrombolytic efficacy and thrombus targetability of RGDS-liposomes encapsulating subtilisin FS33 in vivo). // Xue Gong Cheng Xue Za Zhi. 2010. 27. (2). 332-336.
Wang C.T., Ji B.P., Li B. et al. Purification and characterization of a fibrinolytic enzyme of Bacillus subtilis DC33, isolated from Chinese traditional Douchi // J. Ind. Microbiol. Biotechnol. 2006. 33. (9). 750-758.
Wang S., Deng Z., Li Q. et al. A novel alkaline serine protease with fibrinolytic activity from the polychaete, Neanthes japonica // Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 2011. 159. (1). 18-25.
Yan F., Yan J., Sun W. et al. Thrombolytic effect of subtilisin QK on carrageenan induced thrombosis model in mice. // J Thromb Thrombolysis. 2009. 28. (4). 444-448.

About Authors (Correspondence):

Madonov P.G. – doctor of medical sciences, professor, head of the chair for pharmacology, clinical pharmacology and evidentiary medicine, e-mail: madonov@scpb.ru

Mishenina S.V. – candidate of medical sciences, associated professor of the chair for pharmacology, clinical pharmacology and evidentiary medicine

Kinsht D.N. – doctor of medical sciences, professor, head of the chair for pharmacology, clinical pharmacology and evidentiary medicine

Kikhtenko N.V. – deputy head of research department

Received: 31/08/2016